Groupe Immunité des Muqueuses et Agents Pathogènes, PRES de Lyon, Université Jean Monnet, IFRESIS et CHU de Saint-Etienne, 42023 Saint-Etienne cedex 02, France.
Expert Rev Anti Infect Ther. 2012 Feb;10(2):167-83. doi: 10.1586/eri.11.173.
Women from developing countries, in which the prevalence of HIV infection is very high, are at risk of becoming infected without having the possibility of personally controlling this risk. Therefore, there is an urgent need to develop anti-HIV vaginal microbicide strategies. This review considers the modes of entry of HIV through the mucosa of the female genital tract, the different classes of vaginal microbicide compounds, the mode of delivery of these drugs, the aims and methods of in vitro and animal experiments at the preclinical stage, the results of the Phase III trials conducted in different countries, including the ongoing assays, and the future orientations for the next 5 years with a discussion relative to antiviral resistance, combination strategies and development of new-generation compounds.
发展中国家的妇女感染艾滋病毒的比例非常高，她们有可能在无法个人控制这种风险的情况下感染艾滋病毒。因此，迫切需要制定抗艾滋病毒阴道杀微生物剂战略。本综述考虑了艾滋病毒通过女性生殖道黏膜进入的途径、不同类别的阴道杀微生物剂化合物、这些药物的输送方式、临床前阶段的体外和动物实验的目的和方法、在不同国家进行的 III 期试验的结果，包括正在进行的试验，以及未来 5 年的发展方向，讨论了与抗病毒耐药性、联合策略和新一代化合物的开发有关的问题。
